MICHAEL MILLER: Open Payments
NPI 1881039931 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,026 in 96 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $2,026
Food & beverage: $2,026
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 14 | $431 |
| ABBVIE INC. | 15 | $270 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $190 |
| Neurocrine BioSciences, Inc. | 5 | $141 |
| Janssen Pharmaceuticals, Inc | 5 | $132 |
| Lundbeck LLC | 6 | $130 |
| Tris Pharma Inc | 5 | $112 |
| E.R. Squibb & Sons, L.L.C. | 5 | $111 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| Teva Pharmaceuticals USA, Inc. | 5 | $99 |
Products named: Auvelity, VRAYLAR, CAPLYTA, INGREZZA, REXULTI, SPRAVATO, COBENFY, TRINTELLIX.
Industry payments across TX — which companies pay providers there.
